Last Friday, our team came together for an all-hands meeting to share the latest company updates, discuss ongoing projects, and explore new initiatives across operations and R&D.

The discussion included updates on our lead program, DualFAPi, along with advances in the initial ²¹¹At-radiolabeling of our TetraKit-based compounds.

At TetraKit, we aim to advance next-generation radioligand therapies to improve outcomes and quality of life for patients facing hard-to-treat cancers. This is made possible by the strong collaboration of our team☢️